Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
2010/09/07 by Charles S. Grob, Alicia L. Danforth, Alicia Danforth +7 · 66 citations
Psychology · Neuroscience · Medicine · #Psychedelics and Drug Studies #Pain Management and Placebo Effect #Cannabis and Cannabinoid Research
paper · doi:10.1001/archgenpsychiatry.2010.116
Abstract
CONTEXT: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. OBJECTIVE: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety. DESIGN: A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin. SETTING: A clinical research unit within a large public sector academic medical center. PARTICIPANTS: Twelve adults with advanced-stage cancer and anxiety. MAIN OUTCOME MEASURES: In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment. RESULTS: Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance. CONCLUSIONS: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00302744.
Citations
Cited by
- Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
- Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder
- Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy
- Psychiatry & the psychedelic drugs. Past, present & future
- Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs
- Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
- Psychedelic drugs for psychiatric disorders
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
- Psychedelics
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
- An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin
- Existential feelings as a phenomenological framework for psychedelic therapy
- Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
- Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
- Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms
- Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
- Therapeutic use of psilocybin: Practical considerations for dosing and administration
- Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
- Fearful symmetry in altered states: a bi-logic account of psychedelic action
- The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
- Observational cohort study of a group-based VR program to improve mental health and wellbeing in people with life-threatening illnesses
- Phenomenology, Structure, and Dynamic of Psychedelic States
- Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
- De Novo Biosynthesis of Antidepressant Psilocybin in <i>Escherichia coli</i>
- Psychedelic therapies and belief change: are there risks of epistemic harm or epistemic injustice?
- Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners
- Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use
- Peak Experiences Matter
- Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review
- Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
- Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
- Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin
- Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
- Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
- Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. [europepmc]
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. [europepmc]
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. [europepmc]
- Broadband cortical desynchronization underlies the human psychedelic state. [europepmc]
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. [europepmc]
- Enhanced repertoire of brain dynamical states during the psychedelic experience. [europepmc]
- Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. [europepmc]
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. [europepmc]
- Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. [europepmc]
- The role of serotonin 5-HT2A receptors in memory and cognition. [europepmc]
- LSD-induced entropic brain activity predicts subsequent personality change. [europepmc]
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. [europepmc]
- The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. [europepmc]
- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. [europepmc]
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. [europepmc]
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. [europepmc]
- Psychedelics Promote Structural and Functional Neural Plasticity. [europepmc]
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. [europepmc]
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. [europepmc]
- Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. [europepmc]
- Dynamic coupling of whole-brain neuronal and neurotransmitter systems. [europepmc]
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. [europepmc]
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. [europepmc]
- The neural basis of psychedelic action. [europepmc]
- Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. [europepmc]
Related